# A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

> **NCT04256421** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 490 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04256421
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-04
- **Primary completion:** 2022-09-06
- **Final completion:** 2025-07-31
- **Target enrollment:** 490 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256421, "A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04256421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*